Caplin Point Lab Q4 FY26 Earnings Call — Analysis (NSE: CAPLIPOINT)

Caplin Point FY26 profit up 20% on ₹2,300 Cr revenue; US own-label crosses ₹100 Cr; capex program on track with ₹510 Cr residual spend guided over 18–24 months.

14 May 2026 · Analysis by Alpha Inflection

The take

Revenue (FY26) ₹2,300 Cr ( +13% YoY ) , Q4FY26 +19.45% . New guidance — FY27 us own-label revenue ₹200 Cr . New story: Injectable capacity build-out .

Results

Q4FY26 revenue ₹600.16 Cr (+19.45% YoY), net profit ₹172.88 Cr (+19.32% YoY); FY26 revenue ₹2,300 Cr (+13% YoY), PAT growth 20% YoY, operating cash flow ₹523 Cr, cash reserves ₹1,471 Cr.

Financial highlights

Guidance

US Caplin Steriles topline growth guided at 25–30% for FY27, own-label revenue target to double to ~₹200 Cr; Mexico sales guided at $4 Mn over next two quarters.

What management committed to

• [Caplin Point] will have 17 injectable lines for USA and other regulated markets in the next two-to-three years. — 17 injectable lines, FY28-FY29
• [Caplin Point] will supply $10 million worth of products to Chile over the next 18 months from the 135 registrations received. — $10 million, FY27-FY28
• [Caplin Point] will launch brand marketing in the CNS segment in Dominican Republic, Guatemala, and Nicaragua starting September 2026. — null, Q2FY27
• [Caplin Point] plans to achieve sales of around $4 million in Mexico in the coming two quarters. — $4 million, H1FY27
• [Caplin Point] will double its US own-label revenue to approximately ₹200 Cr in FY27. — ₹200 Cr, FY27
• [Caplin Point] expects Caplin Steriles (US) revenue to grow 25–30% in FY27. — 25–30%, FY27
• [Caplin Point] will spend ₹510 Cr on identified capex projects over the next 18–24 months. — ₹510 Cr, FY27-FY28
• [Caplin Point] will complete another ANDA acquisition in the coming weeks. — null, Q1FY27
• [Caplin Point] will set up a liquid manufacturing facility in Central America, which is expected to increase shelf space in independent pharmacies from 41% to 57%. — null, null
• [Caplin Point] will acquire a distribution company in Chile, Mexico, or Brazil to expand private market reach. — null, null

Key themes

Injectable capacity build-out and regulated market scaling

How the narrative shifted

• Injectable capacity build-out: Management is building 17 injectable lines across facilities with digitalisation and visual SOPs, positioning Caplin among the few Indian companies with such scale in sterile injectables.
• US market scaling with own-label: Own-label US business reached ₹100 Cr in its first full year without cannibalising B2B; management guides doubling to ₹200 Cr and 25-30% overall CSL growth in FY27.
• LATAM distribution deepening: The company is expanding into Chile, Mexico, and Brazil through registrations, tenders, and potential distribution acquisitions, aiming to own the last-mile private market reach.
• Regulatory approvals pipeline: Total ANDAs now 60, with 10 approvals in FY26 and 15 acquired; 54 filings in non-US regulated markets such as Canada, Europe, Australia, South Africa signal future revenue diversification.
• Cash-rich strategic flexibility: Zero debt, ₹1,471 Cr cash, and strong operating cash flow provide capacity to fund capex, acquisitions, and R&D simultaneously without dilution.
• Anti-fragile supply chain model: The model of keeping 6-month inventory near customers in own warehouses insulates the business from global supply chain disruptions and currency swings.
• Complex injectables and R&D focus: R&D spend crossed ₹100 Cr (5% of sales) targeting hormone injections, inhalers, PFS, BAGS, BFS, LYO, and ophthalmic, broadening the product mix into complex, higher-margin segments.
• Global macro volatility as opportunity: Management views geopolitical tensions and debt crises as favorable for Caplin’s unique model, asserting that crisis events historically accelerated its growth and profitability.

Operational commentary

• US: Total ANDAs 60 (10 approved in FY26, 15 acquired); own-label crossed ₹100 Cr revenue in first full year, 30 products launched, 15 more planned in FY27; Caplin Steriles EBITDA margin at 30% (FY26) up from 27.9%.
• LATAM – Chile: 135 product registrations received; $10 Mn supply planned over next 18 months; evaluating two distribution companies for acquisition; bio-studies underway for 40+ high-margin products.
• LATAM – Mexico: 25 registrations; won 8-product two-year tender and an oncology tender (4 products via Chinese partner); $4 Mn sales expected in next two quarters; land purchased for own factory (16% price advantage in tenders).
• LATAM – Central America: 41% shelf space in independent pharmacies; plan to set up liquid manufacturing facility to lift shelf space to 57%; brand marketing launch in CNS segment in Dominican Republic, Guatemala, Nicaragua from Sep 2026.
• Capacity: 17 injectable lines planned over 2–3 years; Phase-III injectable plant at advanced stage; IV bag line capacity tripling; oncology injection plant capitalized in Apr 2026; capex balance ₹510 Cr to be spent over 18–24 months.
• R&D spend crossed ₹100 Cr (5% of sales) for FY26; focus on hormone injections, inhalers, and complex sterile technologies (PFS, BAGS, BFS, LYO, cartridges, ophthalmic).
• Inorganic: actively seeking meaningful acquisition of a facility and distribution companies in LATAM/US; ANDA acquisitions ongoing; discipline on not pursuing vanity acquisitions.
• Cash & balance sheet: zero debt, ₹1,471 Cr cash, ₹2,726 Cr liquid assets; net worth grew 26% to ₹3,331 Cr; forex translation reserve gain of ₹141 Cr added to reserves.

Analyst Q&A

• Q. How will management prioritize between inorganic opportunities, incremental capex, and higher shareholder payouts given growing cash generation?

  Chairman emphasized waiting for meaningful acquisitions, not vanity deals; priority is completing injectable facilities (17 lines), complex R&D, and increasing registrations in larger geographies; inorganic growth will be opportunistic, not rushed.

• Q. Why did receivables grow materially ahead of revenue?

  CFO explained 11 days of the 136-day figure is due to FCTR not impacting P&L; adjusted receivables at 125 days, within 100–120 day comfort range. A large tender in El Salvador shipped in Feb–Mar will be collected by Q2FY27. Chairman added that any delay in dollar-denominated receivables could benefit margins due to INR depreciation.

• Q. What is the outlook for FY27 top line and margins?

  Management stated the best period is yet to come in 2–3 years; did not give specific quarterly/yearly guidance but expressed confidence in doing well; noted that inorganic opportunities could add growth in 6 months to a year, but they will not grab anything.

• Q. What drove the exceptional QoQ revenue growth in LATAM ex-US?

  CFO attributed the jump from ₹432 Cr to ₹470 Cr sequentially to the large El Salvador tender supplies of ~₹50–55 Cr in the quarter; underlying growth normalizing.

• Q. Can the US growth rate of 20–25% be sustained?

  Vivek Partheeban said they are confident of sustaining and even growing further; order book is full for six months; own-label target is to double to ₹200 Cr; CSL overall growth guided at 25–30% for next year.

• Q. What is the profile of acquisitions being considered?

  Vivek noted they evaluate opportunities weekly – US, LATAM, domestic; focus is on good distribution entities in new/early markets and opportunistic ANDA acquisitions to balance pipeline without stretching R&D capacity.

• Q. What is the impact of global macro volatility and Middle East tensions on the business?

  Chairman stated the anti-fragile model with 6-month inventory near customers and own warehouses insulates them; they see crisis as opportunity; no major impact on margins as they do not sell on credit to importers and have pricing power through own subsidiaries.

• Q. Can the company maintain double-digit revenue growth and 25–29% PAT margin over FY27–FY29?

  Vivek said they remain confident; asked for patience over next 12–18 months as new markets stabilize; despite drag from API unit and clinical operations, EBITDA margins are 38–39% and PAT 27–28%; expects margins to be maintained or inch up beyond 18–24 months.

• Q. Quantify forex gain for Q4 and FY26.

  CFO gave ₹20–21 Cr realized gain for FY26, with ₹40–50 Cr unrealized gain reflected in receivables; agreed to provide exact other income split offline.

• Q. Breakup of US growth between organic and new launches, and CSL EBITDA margins for Q4 and FY26.

  Vivek stated >90% of US revenue came from older products; new approvals will launch this year. CFO provided CSL EBITDA margin: FY26 30% (₹142 Cr), Q4 FY26 33%.

Research and educational content only. Not investment advice.